Aspirin in primary prevention: sex and baseline risk matter

Lancet. 2009 May 30;373(9678):1821-2. doi: 10.1016/S0140-6736(09)61003-5.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adult
  • Aged
  • Aspirin / adverse effects
  • Aspirin / economics
  • Aspirin / therapeutic use*
  • Cost-Benefit Analysis
  • Female
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / economics
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Male
  • Meta-Analysis as Topic
  • Middle Aged
  • Patient Selection*
  • Primary Prevention / economics
  • Primary Prevention / methods*
  • Quality-Adjusted Life Years
  • Research Design
  • Risk Factors
  • Sex Distribution
  • Thrombosis / epidemiology
  • Thrombosis / etiology
  • Thrombosis / prevention & control*

Substances

  • Fibrinolytic Agents
  • Aspirin